Home » Stocks » RARE

Ultragenyx Pharmaceutical Inc. (RARE)

Stock Price: $118.54 USD -3.88 (-3.17%)
Updated November 30, 4:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 7.24B
Revenue (ttm) 215.08M
Net Income (ttm) -256.36M
Shares Out 61.04M
EPS (ttm) -4.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 30
Last Price $118.54
Previous Close $122.42
Change ($) -3.88
Change (%) -3.17%
Day's Open 122.56
Day's Range 117.52 - 124.54
Day's Volume 529,435
52-Week Range 33.80 - 124.54

More Stats

Market Cap 7.24B
Enterprise Value 6.51B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 61.04M
Float n/a
EPS (basic) -4.38
EPS (diluted) -4.34
FCF / Share -2.89
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 6.84M
Short Ratio 12.50
Short % of Float n/a
Beta 2.16
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 33.64
PB Ratio 11.90
Revenue 215.08M
Operating Income -328.00M
Net Income -256.36M
Free Cash Flow -175.27M
Net Cash 728.85M
Net Cash / Share 11.94
Gross Margin -122.12%
Operating Margin -152.50%
Profit Margin -119.20%
FCF Margin -81.49%
ROA -19.11%
ROE -36.80%
ROIC -42.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (16)

Buy 10
Overweight 1
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$107.06*
(-9.68% downside)
Low
64.0
Current: $118.54
High
128.0
Target: 107.06
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue10451.502.610.13-----
Revenue Growth101.41%1871.48%1863.91%------
Gross Profit94.7150.352.610.13-----
Operating Income-424-371-329-248-148-56.78-32.28-15.99-6.56
Net Income-403-198-302-246-146-64.61-50.29-19.56-7.47
Shares Outstanding56.5849.7842.4539.5936.7828.763.381.381.62
Earnings Per Share-7.12-3.97-7.12-6.21-3.96-2.25-14.87-14.20-4.62
Operating Cash Flow-345-291-254-161-106-44.63-31.20-12.50-5.83
Capital Expenditures-24.83-4.08-2.79-10.19-4.96-2.15-0.41-1.09-0.55
Free Cash Flow-370-295-257-171-111-46.78-31.61-13.60-6.37
Cash & Equivalents75546023438443918853.8386.67-
Total Debt29.76--------
Net Cash / Debt72546023438443918853.8386.67-
Assets1,13572049154156019859.6588.32-
Liabilities48211110766.6528.4813.029.543.98-
Book Value654609383474531185-74.82-27.05-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ultragenyx Pharmaceutical Inc.
Country United States
Employees 740
CEO Emil D. Kakkis

Stock Information

Ticker Symbol RARE
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RARE
IPO Date January 31, 2014

Description

Ultragenyx Pharmaceutical, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; and gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia. In addition, the company is developing UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Arcturus Therapeutics Holdings Inc. to develop additional nucleic acid therapies for rare diseases. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.